Free tool
FAERS Monitor: Amitiza
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021908 or its brand name (Amitiza, Lubiprostone). Reports on generic versions are filed under their own applications.
Reports
9,556
Serious
6,379
67% of reports
Hospitalization
3,148
Death reported
972
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea803
- dyspnoea641
- diarrhoea633
- constipation584
- drug ineffective568
- fatigue544
- pain500
- headache498
- dizziness457
- fall409
- vomiting409
- off label use350
- chronic kidney disease334
- malaise323
- pyrexia305
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 18 |
| 2007 | 98 |
| 2008 | 163 |
| 2009 | 182 |
| 2010 | 215 |
| 2011 | 210 |
| 2012 | 298 |
| 2013 | 315 |
| 2014 | 404 |
| 2015 | 633 |
| 2016 | 905 |
| 2017 | 788 |
| 2018 | 910 |
| 2019 | 883 |
| 2020 | 736 |
| 2021 | 591 |
| 2022 | 435 |
| 2023 | 439 |
| 2024 | 442 |
| 2025 | 476 |
| 2026 | 415 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,603 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 334 | 9.7 | 8.7 | 2,600 |
| constipationSignal | 584 | 5.9 | 5.5 | 2,394 |
| fallSignal | 409 | 2.7 | 2.5 | 445 |
| dyspnoeaSignal | 641 | 2.5 | 2.3 | 587 |
| nauseaSignal | 803 | 2.2 | 2.1 | 567 |
| diarrhoeaSignal | 633 | 2.2 | 2.0 | 405 |
| dizzinessSignal | 457 | 2.0 | 1.8 | 239 |
| pyrexia | 305 | 1.9 | 1.7 | 140 |
| vomiting | 409 | 1.9 | 1.7 | 182 |
| pain | 500 | 1.8 | 1.6 | 179 |
| headache | 498 | 1.7 | 1.6 | 164 |
| malaise | 323 | 1.6 | 1.5 | 78 |
| fatigue | 544 | 1.5 | 1.4 | 106 |
| drug ineffective | 568 | 0.9 | 0.9 | 2 |
| off label use | 350 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.